Partnership focus

Citrine Medicine is a global biopharmaceutical company focused on the development and commercialization of innovative rare and orphan diseases to address high unmet medical needs and improve the lives of patients in the greater China marketplace.

Citrine’s current products and clinical programs were in-licensed through development and commercialization agreements. Partnering and scientific collaborations are key elements of Citrine Medicine’s strategy. 

For more information, please contact our partnering team:

Current partners
  • Bioprojet SCR is a research-based pharmaceutical company, which is dedicated to creation of new therapeutic molecules. The objective of the company was and still is to use discoveries in fundamental research to create and develop drugs, which could become new therapeutic classes. 

    In parallel, Bioprojet has acquired the commercial licenses or the worldwide rights for drugs whose active molecules are considered within its areas of expertise and continues their development to perfect new formulations, create combinations and expand their indications.

    Today Bioprojet is present in seven European countries and its future research-oriented development is supported with a center where the Biochemistry/Molecular Biology, Chemistry, Pharmacology and Pharmacokinetic units create and study about one thousand molecules each year.  

    For more information, please visit
  • Diurnal is a UK-headquartered, European specialty pharma company developing hormone therapeutics for the global market for the life-long treatment of chronic endocrine conditions, including congenital adrenal hyperplasia, adrenal insufficiency and hypogonadism. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

    For more information, please visit